Detailed Information
Cited 3 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
- Authors
- Ozcan, M[Ozcan, Muhit]; Lee, ST[Lee, Seung Tae]; Mensah, F[Mensah, Felix]; Modi, D[Modi, Dipenkumar]; Fossa, A[Fossa, Alexander]; Kim, WS[Kim, Won Seog]; Paszkiewicz-Kozik, E[Paszkiewicz-Kozik, Ewa]; Sawalha, Y[Sawalha, Yazeed]; Sevindik, OG[Sevindik, Omur Gokmen]; Norasetthada, L[Norasetthada, Lalita]; Santoro, A[Santoro, Armando]; Pathiraja, K[Pathiraja, Kumudu]; Chakraborty, S[Chakraborty, Samhita]; Marinello, P[Marinello, Patricia]; Lavie, D[Lavie, David]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.